IVVD
Invivyd, Inc. · Healthcare
1.76
1.12%(−0.02)
Close PriceLast Updated: — ET
52W L: $0.4652W H: $3.07
Invivyd, Inc. · Healthcare
Allen Robert D. III
officer: Chief Scientific Officer
99,000 SH @ $0.00
2026-02-15
Allen Robert D. III
officer: Chief Scientific Officer
18,189 SH @ $1.54
2026-02-17
Allen Robert D. III
officer: Chief Scientific Officer
19,392 SH @ $1.58
2026-02-18
Allen Robert D. III
officer: Chief Scientific Officer
99,000 SH @ $0.00
2026-02-15
Green Julie
officer: Chief Human Resources Officer
99,000 SH @ $0.00
2026-02-15
Green Julie
officer: Chief Human Resources Officer
19,663 SH @ $1.54
2026-02-17
Green Julie
officer: Chief Human Resources Officer
20,964 SH @ $1.58
2026-02-18
Green Julie
officer: Chief Human Resources Officer
99,000 SH @ $0.00
2026-02-15
Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate Transcript
The company said its Phase 3 DECLARATION trial evaluating VYD2311 for COVID-19 prevention has reached a key interim milestone.
NEW HAVEN, Conn., April 09, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced progress in its REVOLUTION clinical program for VYD2311, a novel monoclonal antibody investigational candidate for the prevention of symptomatic COVID-19. Invivyd also announced today the discovery and advancement of a novel, potentially first- and best-in-class measles monoclonal antibody candidate for treatment and prevention of measles discovered using Invivyd's proprietary technology.
NEW HAVEN, Conn., April 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on April 1, 2026, Invivyd granted 16 newly hired non-executive employees options to purchase an aggregate of 1,083,750 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.
Invivyd, Inc. (NASDAQ: IVVD - Get Free Report) has received a consensus recommendation of "Hold" from the six analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have assigned a buy recommendation to the company. The
NEW HAVEN, Conn., March 30, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Robert Allen, Ph.D., Chief Scientific Officer at Invivyd, presented as part of the Antibodies for Infectious Disease Workshop at the World Vaccine Congress Washington. Dr. Allen's presentation, titled “Developing mAb Therapies that Keep Pace with Rapidly Evolving Viral Threats,” conveyed the ability of monoclonal antibodies to address virus variation.